Navigation Links
Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
Date:5/20/2009

duct candidates, the conduct, timing and results of future clinical trials, and expectations of the future expansion of our product pipeline and collaborations. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2009, filed with the SEC on May 11, 2009, as well as other filings by the company with the SEC.

    Contact Information

    US Media:                             European Media:
    Andrea tenBroek/Chris Stamm           Ludger Wess
    (781)-684-0770                  
'/>"/>
SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014 Orexigen Therapeutics, Inc. (Nasdaq: ... Patent and Trademark Office (PTO) has issued a patent ... for weight loss. NB32 is a fixed-dose combination of ... U.S. Patent No. 8,815,889 claims methods for treating insulin ... patent expires in 2024. If NB32 is approved for ...
(Date:9/2/2014)... SEATTLE , Sept. 2, 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ... , M.D., President and Chief Executive Officer, will present at ... Conference in New York on Tuesday, ... A live and archived webcast of the presentation will be ... the "News & Events" section. About Oncothyreon ...
(Date:9/2/2014)... Sept. 2, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or ... The orders consist of three large odour control systems for ... "These orders are consistent with the market resurgence ... Bruijns , President and CEO. "After a difficult period of ... now beginning to see sales growth. Our lower cost structure, ...
(Date:9/2/2014)... 2, 2014  Spherix Incorporated (SPEX) -- an intellectual property development ... property, today announced that the United States Patent & ... in the month of August that are part of ... The issued patents are: , U.S.RE45,065 ... 19, 2014; and , U.S.RE45,095 issued August 26, ...
Breaking Biology Technology:Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 2
... Third Wave Technologies is appointing more new ... to a press release. , ,Maneesh Arora, 37, will become ... has held senior positions in marketing and operations for the ... 35, will be vice president of finance. , ,John Bellano, ...
... investments in 2005 added up to more than $19 million ... report released on Wednesday. , ,The investor tax credits offered ... start to officially track the volume of investments by individuals. ... picture we've had of what's going on in the individual ...
... of financing is vital to a biotech company (it is ... "biotech" in the broadest sense) companies are continually faced with ... development cycle, this week's article will focus on venture capital ... on VC financing results from Burrill and Company's data. Burrill's ...
Cached Biology Technology:State tracks more angel investment, at least $19M last year 2U.S. VC funding flat in 2005 while life science funding grows 2U.S. VC funding flat in 2005 while life science funding grows 3U.S. VC funding flat in 2005 while life science funding grows 4
(Date:9/1/2014)... in the U.S. undergoes a battery of tests designed ... disease. Thousands of children born in the developing world, ... from the disease each year. , A.J. Kumar ... of those deaths. , A Post-Doctoral Fellow in ... George Whitesides, the Woodford L. and Ann A. Flowers ...
(Date:9/1/2014)... nucleotidethe basic building block of DNAcould initiate fragile X syndrome, the ... The Journal of Cell Biology . ... gene on the X chromosome called fragile X mental retardation ... 360 men carry a so-called premutation, in which a series of ... is slightly longer than normal. These repeats are prone to even ...
(Date:9/1/2014)... As nocturnal animals, bats are perfectly adapted to a life ... between the reflected echoes to measure distance to obstacles or ... different echo delays. A study carried out by researchers at ... that this map dynamically adapts to external factors. , ... bat flies in too close to an object, the number ...
Breaking Biology News(10 mins):Faster, cheaper tests for sickle cell 2Faster, cheaper tests for sickle cell 3A nucleotide change could initiate fragile X syndrome 2Zooming in for a safe flight 2
... are labeled a “night owl?report more pathological symptoms related ... for their nocturnal sleeplessness by extending their time in ... time, according to a study published in the April ... (JCSM). , The study, authored by Jason C. Ong, ...
... Southwestern Medical Center have found a new method for ... the most common acute infections in children. , ... by tracking down the virus or bacteria causing it. ... virus may not be present in the blood or ...
... Institutes of Health have discovered how a defect in ... several genes interact to create myelin, a fatty coating ... reliability of their electrical signals. , The discovery ... These disorders can affect the peripheral nervous system—the nerves ...
Cached Biology News:'Night owls' report more insomnia-related symptoms 2Infection detectives use disease 'fingerprints' to track common infections in children 2Infection detectives use disease 'fingerprints' to track common infections in children 3Researchers discover gene crucial for nerve cell insulation 2Researchers discover gene crucial for nerve cell insulation 3
Request Info...
FITC~Bovine Serum Albumin...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
... siRNA service provides the premium quality siRNAs ... Custom siRNAs can be readily ordered online ... sequence, or by providing the sense and ... Silencer Validated and Silencer ...
Biology Products: